BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a clinical-stage biotechnology company developing oral small-molecule therapies for cancers driven by RAS and PI3Kα oncogenes. Its pipeline includes BBO-8520, a dual ON/OFF KRAS G12C inhibitor; BBO-11818, a dual ON/OFF pan-KRAS inhibitor; and BBO-10203, which… From the company’s description.
In fiscal 2025, BridgeBio Oncology Therapeutics, Inc. reported a net loss of $134.04M. Operations used $113.89M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BridgeBio Oncology Therapeutics, Inc. does
In the company’s own words
BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a clinical-stage biotechnology company developing oral small-molecule therapies for cancers driven by RAS and PI3Kα oncogenes. Its pipeline includes BBO-8520, a dual ON/OFF KRAS G12C inhibitor; BBO-11818, a dual ON/OFF pan-KRAS inhibitor; and BBO-10203, which blocks RAS-mediated activation of PI3Kα. The company is evaluating these candidates as single agents and in combinations for cancers including lung, breast, colorectal and pancreatic cancer. Its Phase 1 programs include studies in patients with KRAS-mutant solid tumors and breast and colorectal cancers. The pipeline also supports planned combinations targeting both MAPK and PI3Kα signaling pathways. BridgeBio Oncology Therapeutics was formed following an August 2025 business combination between Helix Acquisition Corp. II and TheRas, Inc., which operated as BridgeBio Oncology Therapeutics; Helix adopted the BridgeBio Oncology Therapeutics name upon completion. The company reports no commercial product revenue, and its business is focused on drug research and clinical development. Its website is https://bbotx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1869105
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BridgeBio Oncology Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BridgeBio Oncology Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BridgeBio Oncology Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BridgeBio Oncology Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BridgeBio Oncology Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”